This article describes American Reinvestment and Recovery Act comparative effectiveness research (CER) data infrastructure (DI) investments and identifies facilitators and barriers to implementation. We reviewed original project proposals, conducted an investigator survey, and interviewed...

Using Medicaid Analytic eXtract (MAX) claims files for 1999 and 2001, the authors describe patterns of prescription drug use and expenditures among dually eligible Medicare and Medicaid beneficiaries for all Medicaid full dually eligible beneficiaries and three important subgroups: the aged,...

New data, prepared for the Centers for Medicare & Medicaid Services, provide detailed state-by-state and national information on prescription drug cost and utilization in 2003 for Medicaid beneficiaries enrolled in both Medicaid and Medicare (“dual eligiblesâ€), whose drug coverage...

The Medicaid Value Program tested interventions to improve care for adult Medicare beneficiaries with multiple chronic conditions. This report presents findings from Mathematica's evaluation; estimates of program effects, produced by the programs themselves; and case studies for the 10...

To provide better value and improve patient care in the U.S. health care system, comparative effectiveness research (CER) needs to be disseminated, implemented, and interpreted. This brief, the second from Mathematica’s Center on Health Care Effectiveness, examines how to put CER into use at...

A retrospective analysis of Medicare claims data examined the relationship between outpatient visits within 14 days after hospital discharge and readmission for beneficiaries with atrial fibrillation or other chronic conditions. About half of those beneficiaries with a hospitalization had an...